Free Trial

SELLAS Life Sciences Group (SLS) Competitors

SELLAS Life Sciences Group logo
$1.80 -0.03 (-1.64%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$1.82 +0.01 (+0.83%)
As of 07/25/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SLS vs. URGN, PHAR, MGTX, GYRE, MNMD, ZVRA, DNTH, DAWN, ATAI, and AUTL

Should you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include Urogen Pharma (URGN), Pharming Group (PHAR), MeiraGTx (MGTX), Gyre Therapeutics (GYRE), Mind Medicine (MindMed) (MNMD), Zevra Therapeutics (ZVRA), Dianthus Therapeutics (DNTH), Day One Biopharmaceuticals (DAWN), atai Life Sciences (ATAI), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry.

SELLAS Life Sciences Group vs. Its Competitors

SELLAS Life Sciences Group (NASDAQ:SLS) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

SELLAS Life Sciences Group has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SELLAS Life Sciences GroupN/AN/A-$30.88M-$0.38-4.74
Urogen Pharma$90.40M9.68-$126.87M-$3.18-5.96

SELLAS Life Sciences Group presently has a consensus price target of $7.00, indicating a potential upside of 288.89%. Urogen Pharma has a consensus price target of $32.86, indicating a potential upside of 73.39%. Given SELLAS Life Sciences Group's higher probable upside, equities research analysts plainly believe SELLAS Life Sciences Group is more favorable than Urogen Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Urogen Pharma
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00

SELLAS Life Sciences Group has a net margin of 0.00% compared to Urogen Pharma's net margin of -150.68%. SELLAS Life Sciences Group's return on equity of -193.67% beat Urogen Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
SELLAS Life Sciences GroupN/A -193.67% -113.02%
Urogen Pharma -150.68%-97,487.15%-49.57%

In the previous week, Urogen Pharma had 7 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 8 mentions for Urogen Pharma and 1 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 1.89 beat Urogen Pharma's score of 0.55 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company Overall Sentiment
SELLAS Life Sciences Group Very Positive
Urogen Pharma Positive

SELLAS Life Sciences Group has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 1.4% of SELLAS Life Sciences Group shares are owned by insiders. Comparatively, 5.1% of Urogen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

SELLAS Life Sciences Group beats Urogen Pharma on 8 of the 15 factors compared between the two stocks.

Get SELLAS Life Sciences Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLS vs. The Competition

MetricSELLAS Life Sciences GroupMED IndustryMedical SectorNASDAQ Exchange
Market Cap$179.60M$3.05B$5.70B$9.50B
Dividend YieldN/A2.37%4.58%4.00%
P/E Ratio-4.7421.3228.3920.08
Price / SalesN/A285.38431.7788.79
Price / CashN/A42.7636.2258.56
Price / Book13.858.378.675.88
Net Income-$30.88M-$55.19M$3.25B$258.89M
7 Day Performance1.69%5.86%4.30%3.71%
1 Month Performance-11.33%17.29%10.57%11.72%
1 Year Performance53.85%4.39%35.68%18.00%

SELLAS Life Sciences Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLS
SELLAS Life Sciences Group
2.323 of 5 stars
$1.80
-1.6%
$7.00
+288.9%
+55.2%$179.60MN/A-4.7410
URGN
Urogen Pharma
4.5124 of 5 stars
$15.46
+1.2%
$32.86
+112.5%
+15.8%$705.49M$90.40M-4.86200High Trading Volume
PHAR
Pharming Group
2.2878 of 5 stars
$10.14
-1.0%
$30.00
+195.7%
+20.7%$702.52M$297.20M-50.72280News Coverage
Upcoming Earnings
Gap Up
MGTX
MeiraGTx
4.2731 of 5 stars
$8.69
+0.8%
$24.00
+176.2%
+64.4%$692.75M$33.28M-3.75300Insider Trade
GYRE
Gyre Therapeutics
0.1464 of 5 stars
$7.10
-1.5%
N/A-49.0%$676.00M$100.64M355.1840Positive News
MNMD
Mind Medicine (MindMed)
1.9796 of 5 stars
$9.95
+12.0%
$25.50
+156.3%
+3.6%$670.91MN/A-7.7140News Coverage
Upcoming Earnings
High Trading Volume
ZVRA
Zevra Therapeutics
3.0903 of 5 stars
$11.73
-2.8%
$23.71
+102.2%
+80.3%$659.98M$23.61M-6.1720
DNTH
Dianthus Therapeutics
1.3253 of 5 stars
$20.74
+1.7%
$53.00
+155.5%
-23.5%$656.06M$6.24M-7.2080Positive News
DAWN
Day One Biopharmaceuticals
2.7115 of 5 stars
$6.40
flat
$29.00
+353.1%
-54.5%$648.72M$131.16M-9.0160News Coverage
ATAI
atai Life Sciences
3.3112 of 5 stars
$3.53
+9.3%
$9.00
+155.0%
+125.9%$647.09M$310K-3.8880News Coverage
High Trading Volume
AUTL
Autolus Therapeutics
2.6132 of 5 stars
$2.43
+0.8%
$9.32
+283.5%
-45.2%$641.40M$10.12M-2.76330

Related Companies and Tools


This page (NASDAQ:SLS) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners